Statement advising caution on interpretation of recent paper on cancer risk & hyperthyroidism issued
(Society for Endocrinology) Caution is advised in interpreting the findings of the recent JAMA Internal Medicine publication1 on radioactive iodine treatment for hyperthyroid patients and cancer mortality. The paper's conclusion that 'in RAI-treated patients with hyperthyroidism, greater organabsorbed doses appeared to be modestly positively associated with risk of death from solid cancer, including breast cancer', has raised concerns among patients and clinicians.
J Clin Endocrinol Metab. 2021 Sep 23:dgab700. doi: 10.1210/clinem/dgab700. Online ahead of print.ABSTRACTRadioactive iodine has been considered a safe and effective therapeutic option for hyperthyroidism secondary to Graves' disease and autonomously functioning thyroid nodules since the mid-20th century. The question of whether I-131 at the doses used for hyperthyroidism might increase the risk of cancer has been investigated in a number of observational cohort studies over the years, with the preponderance of evidence being reassuring as to its safety. In particular, the 1998 Cooperative Thyrotoxicosis Therapy Follow-up S...
CONCLUSION: The results showed that all the AEs and irAEs of all the categories were more prevalent with ICIs.PMID:34162158 | DOI:10.1016/j.intimp.2021.107796
In conclusion, breast cancer risk was reduced long after hypothyroidism diagnosis, but increased among women with treated hyperthyroidism. Futu re studies are needed to determine whether the higher breast cancer risk observed among treated hyperthyroidism could be explained by hyperthyroidism severity, type of treatment or aetiology.
ConclusionsActivity of tissue microsomal reductases varies in thyroid pathology and can be considered as a promising biomarker for differential diagnostics of benign and malignant thyroid tumors.
Despite the biological link between thyroid hormones and breast cancer cell proliferation shown in experimental studies, little is known about the association between hyperthyroidism and breast cancer, as well...
ConclusionMany experimental studies suggest a link between hyperthyroidism/hypothyroidism and BC. We were able to demonstrate an epidemiological association between thyroiditis and an increased BC risk. This shows the need for close monitoring for BC in women with thyroiditis.
CONCLUSIONS: Compared to women with no history of thyroid disorder, hypothyroidism was associated with a lower risk of breast cancer. This was mainly seen among those who received thyroid replacement therapy and had never used menopausal hormone therapy. Among the treatment options for hypothyroidism, levothyroxine had the strongest inverse association with breast cancer risk. PMID: 31918623 [PubMed - as supplied by publisher]
In conclusion, we found elevated levels of circulating FGF-23 with hypercalcemia following the discontinuation of denosumab. FGF-23 might be a surrogate marker for massive bone resorption triggered by discontinuation of long-term denosumab treatment. PMID: 31527321 [PubMed - as supplied by publisher]
Treatment with radioactive iodine associated with long-term risk of death from solid cancers, including breast cancer Related items fromOnMedica Men with high oestrogen levels at greater risk of breast cancer Diabetes risk lower with high intake of fruit and veg Cancer survival rates not improved much in a decade Is crowdfunding for cancer patients paying for ‘quackery’? Is the NHS ready for ‘Cutting edge’ CAR T cell immunotherapy?
(NIH/National Cancer Institute) Findings from a study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published July 1, 2019 in JAMA Internal Medicine.